Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 8, 2014, Pages 1117-1121

  Gaitanis, G ^a   Bassukas, I D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY;

CARCINOMA, BASAL CELL; HUMAN; MULTIMODALITY CANCER THERAPY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, BASAL CELL; COMBINED MODALITY THERAPY; HUMANS; SKIN NEOPLASMS;

EID: 84905858445     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12327     Document Type: Article

References (20)

1. Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer EV,. Trends in non-melanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005; 53: 320-328. (Pubitemid 40979591)
2. Ali FR, Lear JT,. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC. Br J Dermatol 2013; 169: 53-57.
3. Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y,. A comparative study of gene-expression data of basal cell carcinoma and melanoma reveals new insights about the two cancers. PLoS ONE 2012; 7: e30750.
4. Semenovitch I, Sicuro F, Lupi O, Bouskela F,. Evaluation of basal cell carcinoma microcirculation through orthogonal polarization technique. Arch Dermatol Res 2011; 303: 475-479.
5. Carbone A, Viola P, Varrati S, Angelucci D, Tulli A, Amerio P,. Microvessel density and VEGF expression seems to correlate with invasiveness of basal cell carcinoma. Eur J Dermatol 2011; 21: 608-609.
6. Oh CK, Kwon YW, Kim YS, Jang HS, Kwon KS,. Expression of basic fibroblast growth factor, vascular endothelial growth factor and thrombospondin-1 related to microvessel density in nonaggressive and aggressive basal cell carcinomas. J Dermatol 2003; 30: 306-313.
7. Gaitanis G, Nomikos K, Vava E, Alexopoulos EC, Bassukas ID,. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application. J Eur Acad Dermatol Venereol 2009; 23: 1427-1431.
8. Gaitanis G, Bassukas ID,. Immunocryosurgery for non-superficial basal cell carcinoma: a prospective, open-label phase III study for tumours ≤2 cm diameter. Acta Derm Venereol 2014; 94: 1-7.
9. Gaitanis G, Mitsou G, Tsiouri G, Alexis I, Bassukas ID,. Cryosurgery during imiquimod cream treatment ("immunocryosurgery") for Bowen's disease of the skin: a case series. Acta Derm Venereol 2010; 90: 533-534.
10. Bassukas ID, Gamvroulia C, Zioga A, Nomikos K, Fotika C,. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna. Int J Dermatol 2008; 47: 519-521. (Pubitemid 351560323)
11. Gaitanis G, Nomikos K, Vlachos C, Bassukas ID,. Immunocryosurgery for patients with therapeutically challenging basal cell carcinomas: report of two representative cases. J Dermatolog Treat 2012; 23: 70-71.
12. Gaitanis G, Kalogeropoulos C, Bassukas ID,. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas. Br J Ophthalmol 2011; 95: 890-892.
13. Apalla Z, Karteridou A, Lallas A, et al,. Letter: immunocryotherapy for difficult-to-treat basal cell carcinoma of the eyelid. Dermatol Surg 2013; 39: 146-147.
14. Bassukas ID, Gaitanis G,. Combination of cryosurgery and topical imiquimod: does timing matter for successful immunocryosurgery? Cryobiology 2009; 59: 116-117.
15. NCCN Guidelines: Basal cell and squamous cell skin cancers. Version 1.2013. URL https://subscriptions.nccn.org/gl-login.aspx?ReturnURL=http://www. nccn.org/professionals/physician-gls/pdf/nmsc (last accessed: 15 July 2013).
16. Rogers DJ, Ojha S, Maurer R, Hartnick CJ,. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 2013; 139: 496-501.
17. Kahana A, Lee BJ, Flint A, Elner VM,. Periocular epithelioid hemangioma: response to bevacizumab and vascular pathogenesis. Arch Ophthalmol 2012; 130: 1209-1212.
18. Paul S, Stone DU,. Intralesional bevacizumab use for invasive ocular surface squamous neoplasia. J Ocul Pharmacol Ther 2012; 28: 647-649.
19. Edelmann ML, Utter ML, Klein LV, Wotman KL,. Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica). Vet Ophthalmol 2013; 16: 219-224.
20. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ,. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133: 1188-1196.